Pre-clinical study of drug combinations that reduce breast cancer burden due to aberrant mTOR and metabolism promoted by LKB1 loss. - Wikidata - awgldk - TriplyDB

Pre-clinical study of drug combinations that reduce breast cancer burden due to aberrant mTOR and metabolism promoted by LKB1 loss.

Pre-clinical study of drug combinations that reduce breast cancer burden due to aberrant mTOR and metabolism promoted by LKB1 loss.

http://www.wikidata.org/entity/Q35149656

about

Targeting LKB1 in cancer - exposing and exploiting vulnerabilities Clinical Relevance of Liver Kinase B1(LKB1) Protein and Gene Expression in Breast Cancer Computational Inferences of the Functions of Alternative/Noncanonical Splice Isoforms Specific to HER2+/ER-/PR- Breast Cancers, a Chromosome 17 C-HPP Study.SCD1 is associated with tumor promotion, late stage and poor survival in lung adenocarcinoma.Functional characterization of AMP-activated protein kinase signaling in tumorigenesis.Heightening Energetic Stress Selectively Targets LKB1-Deficient Non-Small Cell Lung Cancers.Activation of tumor suppressor LKB1 by honokiol abrogates cancer stem-like phenotype in breast cancer via inhibition of oncogenic Stat3.Raptor mediates the antiproliferation of cardamonin by mTORC1 inhibition in SKOV3 cells.

P2860

Q26801412-5974003D-7A52-4A03-8877-AF1F43BFDA9C Q36579447-A65E6758-F56B-40EC-857F-92F043FB382A Q36596946-D1F8BC14-D459-46A1-B4E3-80CD083B6AE1 Q37457747-F89317AE-3666-4C1A-BEA5-E72A694CFB7B Q38807302-9922347B-9D12-437C-9BC0-F0DCAF86058A Q38819110-E0D6C17C-831A-43D0-8EE6-152ACE506025 Q47866372-915BBAF7-5F0A-4E2F-BA01-681F765E13DF Q50231785-2A4913E7-3DDE-4DCB-8EAA-5088F7EE036F

P2860

Pre-clinical study of drug combinations that reduce breast cancer burden due to aberrant mTOR and metabolism promoted by LKB1 loss.

http://www.wikidata.org/entity/Q35149656

description

2014 nî lūn-bûn

@nan

2014 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած

@hyw

2014 թվականի դեկտեմբերին հրատարակված գիտական հոդված

@hy

2014年の論文

@ja

2014年論文

@yue

2014年論文

@zh-hant

2014年論文

@zh-hk

2014年論文

@zh-mo

2014年論文

@zh-tw

2014年论文

@wuu

name

Pre-clinical study of drug com ...... abolism promoted by LKB1 loss.

@ast

Pre-clinical study of drug com ...... abolism promoted by LKB1 loss.

@en

type

label

Pre-clinical study of drug com ...... abolism promoted by LKB1 loss.

@ast

Pre-clinical study of drug com ...... abolism promoted by LKB1 loss.

@en

prefLabel

Pre-clinical study of drug com ...... abolism promoted by LKB1 loss.

@ast

Pre-clinical study of drug com ...... abolism promoted by LKB1 loss.

@en

P1433

Q35149656-2A126FF7-A39B-4FDB-9342-532008E9F1E9

P1476

Q35149656-68A724DD-446D-4792-822A-6FF7B2770985

P2093

Q35149656-00666CD6-0520-44C2-B52A-1D36EF1ECD03

Q35149656-442BBE20-10EB-4222-92CC-3791057F9964

Q35149656-5CD6FD32-CCD2-4F10-BE8C-DE31FE50410A

Q35149656-6411F6A9-5D12-45BC-B7D2-CD3C6A8BE190

Q35149656-AF825BA1-D5DF-4E98-B24C-EDDAA01C43FF

P2860

Q35149656-02107E0D-3AC9-4CBF-99D4-0260CD20D7CA

Q35149656-0F0F88EF-C814-43A1-B097-1B439DACA68A

Q35149656-1771E1D8-DA04-434C-90E9-9DB53D58D5E9

Q35149656-1E19C60E-244E-4B82-B505-506FB6B9D5C1

Q35149656-26818262-4F71-48D0-967A-5852FEFADEE8

Q35149656-2AA35073-E5EF-4747-B39C-185D2346FF43

Q35149656-39D9D435-F6C8-4A8E-BA1A-ED24D4F19A2C

Q35149656-3A77CF85-5043-4D00-AA18-ED6523C71D77

Q35149656-3E5CBCEF-694F-48CE-BAD9-A38E244E7E86

Q35149656-3E712B2C-EBC9-4C93-A989-EE3EA065E06B

P304

Q35149656-1E3CA25F-CCD3-4EFE-B0A7-5102233811FF

P31

Q35149656-5A4A8B48-1B6E-4F89-B01E-6F866E88A4B6

P356

Q35149656-51FB27A1-7154-4A56-95A7-366D7A2CEFCB

P407

Q35149656-276560E7-A6E1-459D-822A-3ED30B743EF1

P433

Q35149656-C058AE2B-6FA1-44CF-BE64-598CB65C5195

P478

Q35149656-51701ADC-E5F3-4F47-AB99-8479C9DB2761

P577

Q35149656-27C58EDD-EE7A-4AC0-A32B-417D8C8D8EE7

P698

Q35149656-42735857-9438-42F0-9B83-80DAC5DE0472

P932

Q35149656-A8FF77D9-1200-4900-9794-2200C0C0D68C

P356

ONCOTARGET.2818

P1433

P1476

Pre-clinical study of drug com ...... abolism promoted by LKB1 loss.

@en

P2093

Chris V Bowen

http://www.w3.org/2001/XMLSchema#string

Donna Goguen

http://www.w3.org/2001/XMLSchema#string

Heidi A Bentley

http://www.w3.org/2001/XMLSchema#string

Paola A Marignani

http://www.w3.org/2001/XMLSchema#string

Rafaela Andrade-Vieira

http://www.w3.org/2001/XMLSchema#string

P2860

Complexes between the LKB1 tumor suppressor, STRAD alpha/beta and MO25 alpha/beta are upstream kinases in the AMP-activated protein kinase cascade

Regulation of AMP-activated protein kinase by a pseudosubstrate sequence on the gamma subunit

Rictor, a novel binding partner of mTOR, defines a rapamycin-insensitive and raptor-independent pathway that regulates the cytoskeleton

LKB1 is a master kinase that activates 13 kinases of the AMPK subfamily, including MARK/PAR-1

LKB1 signaling in mesenchymal cells required for suppression of gastrointestinal polyposis

Mammalian target of rapamycin up-regulation of pyruvate kinase isoenzyme type M2 is critical for aerobic glycolysis and tumor growth

Integrative genomic and proteomic analyses identify targets for Lkb1-deficient metastatic lung tumors

The tumor suppressor LKB1 kinase directly activates AMP-activated kinase and regulates apoptosis in response to energy stress

NVP-BEZ235, a dual PI3K/mTOR inhibitor, prevents PI3K signaling and inhibits the growth of cancer cells with activating PI3K mutations.

TSC2 mediates cellular energy response to control cell growth and survival

P304

12738-12752

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.18632/ONCOTARGET.2818

http://www.w3.org/2001/XMLSchema#string

P407

P433

24

http://www.w3.org/2001/XMLSchema#string

P478

5

http://www.w3.org/2001/XMLSchema#string

P577

2014-12-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

25436981

http://www.w3.org/2001/XMLSchema#string

P932

4350354

http://www.w3.org/2001/XMLSchema#string